NSTE-ACS患者PCI术后替格瑞洛单药与双联抗血小板治疗的比较:TWILIGHT-ACS预设亚组分析
TWILIGHT-ACS研究为TWILIGHT试验的预设亚组分析,纳入9006例高危PCI患者,经3个月替格瑞洛联合阿司匹林双联抗血小板治疗后,7119例无事件且依从的患者随机接受替格瑞洛单药或联合阿司匹林治疗12个月。在NSTE-ACS患者(n=4614)中,替格瑞洛单药较联合阿司匹林显著降低BARC 2、3或5型出血风险53%(3.6% vs 7.6%,HR 0.47,95%CI 0.36-0.61,P<0.001),且不增加全因死亡、心肌梗死或卒中复合终点(4.3% vs 4.4%,HR 0.97,95%CI 0.74-1.28,P=0.84)。
要点
- NSTE-ACS患者PCI术后完成3个月DAPT后,替格瑞洛单药较联合阿司匹林显著降低出血风险。
- 替格瑞洛单药不增加全因死亡、心肌梗死或卒中复合缺血终点。
- 出血获益在NSTE-ACS患者中较稳定患者更显著(Pint=0.03)。
核心结论
- 在完成PCI术后初始3个月DAPT的NSTE-ACS或稳定患者中,替格瑞洛单药较替格瑞洛联合阿司匹林减少临床相关出血事件,且不增加缺血风险。
- 替格瑞洛单药在出血事件方面的获益在NSTE-ACS患者中更为显著。
研究设计与样本
- TWILIGHT试验的预设亚组分析,纳入9006例接受药物洗脱支架PCI的高危患者。
- 经3个月替格瑞洛联合阿司匹林DAPT后,7119例依从且无事件患者双盲随机接受替格瑞洛加安慰剂或替格瑞洛加阿司匹林治疗12个月。
- 主要终点为BARC 2、3或5型出血,关键次要终点为全因死亡、心肌梗死或卒中的复合终点。
主要发现
- NSTE-ACS患者(n=4614)中,替格瑞洛单药组BARC 2、3或5型出血发生率为3.6%,联合阿司匹林组为7.6%(HR 0.47,95%CI 0.36-0.61,P<0.001)。
- 稳定患者(n=2503)中,替格瑞洛单药组出血发生率为4.8%,联合阿司匹林组为6.2%(HR 0.76,95%CI 0.54-1.06,P=0.11;名义Pint=0.03)。
- NSTE-ACS患者中全因死亡、心肌梗死或卒中发生率两组分别为4.3%和4.4%(HR 0.97,95%CI 0.74-1.28,P=0.84)。
- 无NSTE-ACS患者中全因死亡、心肌梗死或卒中发生率两组分别为3.1%和3.2%(HR 0.96,95%CI 0.61-1.49,P=0.85),临床呈现与治疗间无交互作用(Pint=0.96)。
关键数值与推荐
- NSTE-ACS患者中替格瑞洛单药降低BARC 2、3或5型出血的HR为0.47(95%CI 0.36-0.61,P<0.001)。
- 稳定患者中替格瑞洛单药降低BARC 2、3或5型出血的HR为0.76(95%CI 0.54-1.06,P=0.11)。
- 出血获益的亚组交互名义P值为0.03。
- 缺血复合终点的亚组交互P值为0.96。
临床怎么用
- 对于高危PCI术后已完成3个月替格瑞洛联合阿司匹林DAPT且无事件的患者,可考虑转为替格瑞洛单药治疗以降低出血风险。
- NSTE-ACS患者从替格瑞洛单药中的出血获益更为明显,决策时可结合缺血与出血风险个体化评估。
局限性
- 本研究为预设亚组分析,非主要终点Power计算。
- 结果仅适用于完成3个月DAPT后无事件且依从的患者群体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to determine the effect of ticagrelor monotherapy on clinically relevant bleeding and major ischaemic events in relation to clinical presentation with and without non-ST elevation acute coronary syndromes (NSTE-ACS) among patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). METHODS AND RESULTS: We conducted a pre-specified subgroup analysis of The Ticagrelor With Aspirin or Alone in High Risk Patients After Coronary Intervention (TWILIGHT) trial, which enrolled 9006 patients with high-risk features undergoing PCI with DES. After 3 months of dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin, 7119 adherent and event-free patients were randomized in a double-blind manner to ticagrelor plus placebo versus ticagrelor plus aspirin for 12 months. The primary outcome was Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding while the composite of all-cause death, myocardial infarction (MI), or stroke was the key secondary outcome. Among patients with NSTE-ACS (n = 4614), ticagrelor monotherapy reduced BARC 2, 3, or 5 bleeding by 53% [3.6% vs. 7.6%; hazard ratio (HR) 0.47; 95% confidence interval (CI) 0.36-0.61; P < 0.001) and in stable patients (n = 2503) by 24% (4.8% vs. 6.2%; HR 0.76; 95% CI 0.54-1.06; P = 0.11; nominal Pint = 0.03). Rates of all-cause death, MI, or stroke among those with (4.3% vs. 4.4%; HR 0.97; 95% CI 0.74-1.28; P = 0.84) and without (3.1% vs. 3.2%; HR 0.96; 95% CI 0.61-1.49; P = 0.85) NSTE-ACS were similar between treatment arms irrespective of clinical presentation (Pint = 0.96). CONCLUSION: Among patients with or without NSTE-ACS who have completed an initial 3-month course of DAPT following PCI with DES, ticagrelor monotherapy reduced clinically meaningful bleeding events without increasing ischaemic risk as compared with ticagrelor plus aspirin. The benefits of ticagrelor monotherapy with respect to bleeding events were more pronounced in patients with NSTE-ACS. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02270242.
引用
- Baber U, Dangas G, Angiolillo DJ, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020. PMID: 33085967. doi:10.1093/eurheartj/ehaa670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。